TMP 301
Alternative Names: Heptares 25; HTL-0014242; HTL14242; TMP-301Latest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator Sosei Heptares
- Developer Nxera Pharma; Tempero Bio
- Class Antipsychotics; Anxiolytics; Behavioural disorder therapies; Benzonitrile; Drug withdrawal therapies; Neuroprotectants; Nitriles; Pyrimidines; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholism
- Phase I Cocaine-related disorders; Substance-related disorders
- Discontinued Anxiety disorders; Neurological disorders; Psychiatric disorders
Most Recent Events
- 14 Nov 2024 Phase-II clinical trials in Alcoholism in USA (PO) (NCT06648655)
- 18 Oct 2024 Tempero Bio plans a phase-II trial for Alcoholism in December 2024 (PO), (NCT06648655),
- 18 Oct 2024 Tempero Bio plans to initiate a phase I trial for Cocaine-related disorders (PO) (NCT06648668)